Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

The top 10 most expensive drugs of 2013
Fierce Pharma
Tuesday, October 14, 2014 - 10:05am
tags:
drug pricing, Soliris, Alexion, Naglazyme, Biomarin, Kalydeco, Vertex, Cinryze, Shire, Sprycel, Bristol-Myers Squibb, Pomalyst, Celgene, Xyrem, Jazz Pharmaceuticals, Erbitux, Merck KGaA, Revlimid, Questcor, Mallinckrodt, H.P. Acthar Gel
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?
WSJ Pharmalot
Tuesday, October 14, 2014 - 9:51am
tags:
AbbVie, drug pricing, hepatitis C, Gilead Sciences
FDA staff wants Pfizer to keep black box warning on anti-smoking drug
Yahoo/Reuters
Tuesday, October 14, 2014 - 9:49am
tags:
FDA, Pfizer, black box, Chantix, smoking cessation
AstraZeneca looks to EU decision for next cancer drug boost
Yahoo/Reuters
Tuesday, October 14, 2014 - 9:48am
tags:
AstraZeneca, Europe, olaparib, ovarian cancer
The Gilead Effect
The Morning Consult
Tuesday, October 14, 2014 - 8:38am
tags:
Gilead Sciences, drug pricing, Sovaldi
NewLink Starts Human Trials For Ebola Vaccine; Stock Soars 23%
Bidness Etc.
Tuesday, October 14, 2014 - 8:29am
tags:
NewLink Genetics, ebola virus, vaccines, VSV-EBOV
Novartis joins an Atlas syndicate to back cancer drug upstart Raze
Fierce Biotech
Tuesday, October 14, 2014 - 8:25am
tags:
Novartis, cancer, Raze, Atlas Venture
First sickle cell patient infused with bluebird bio's stem cells
Seeking Alpha
Tuesday, October 14, 2014 - 8:04am
tags:
sickle cell anemia, Bluebird Bio, stem cells
Johnson & Johnson shares gain after profit beat, raised outlook
Marketwatch
Tuesday, October 14, 2014 - 8:00am
tags:
JNJ, earnings
Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study
The Chairman's Blog
Monday, October 13, 2014 - 4:09pm
tags:
Sarepta Therapeutics, Duchenne Muscular Dystrophy, eteplirsen
Ranbaxy Execs in the U.S. Depart Ahead of Sun Pharma Deal: Report
WSJ Pharmalot
Monday, October 13, 2014 - 4:04pm
tags:
Ranbaxy, Sun Pharma, M&A
Alnylam Drug Scores Against Rare Nerve Disease
Investors.com
Monday, October 13, 2014 - 4:02pm
tags:
Alnylam, Patisiran, familial amyloid polyneuropathy
Bristol-Myers, Otsuka ask judge to nix Abilify kickback suit
Fierce Pharma
Monday, October 13, 2014 - 10:26am
tags:
Bristol-Myers Squibb, Otsuka, kickbacks, Abilify, whistleblower lawsuits
Piper Jaffray Upgrades Vertex Pharmaceuticals Ahead Of Expected Combination Approvals
Yahoo/Benzinga
Monday, October 13, 2014 - 10:19am
tags:
Vertex Pharmaceuticals, cystic fibrosis, VX-809, Kalydeco
Bristol-Myers, Pharmacyclics And Janssen Collaborate On OPDIVO And IMBRUVICA
RTT News
Monday, October 13, 2014 - 10:14am
tags:
Bristol-Myers Squibb, Pharmacyclics, Janssen, Opdivo, Imbruvica
Medtronic seeks EU approval for $43 bln Covidien deal
Yahoo/Reuters
Monday, October 13, 2014 - 9:42am
tags:
Medtronic, Europe, M&A, Covidien, devices
Companies That Could Develop An Enterovirus Treatment
Yahoo/Benzinga
Monday, October 13, 2014 - 9:16am
tags:
enterovirus, AbbVie, Alnylam, Gilead Sciences, Bristol-Myers Squibb, Merck, Biocryst, Chimerix, Tekmira, Sarepta Therapeutics
Will St. Jude Medical (STJ) Disappoint this Earnings Season?
Yahoo/Zacks.com
Monday, October 13, 2014 - 9:13am
tags:
St. Jude Medical, earnings, devices
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review
Yahoo
Monday, October 13, 2014 - 8:35am
tags:
Pfizer, palbociclib, FDA, advanced breast cancer
What to expect from Johnson & Johnson’s earnings
Marketwatch
Monday, October 13, 2014 - 8:33am
tags:
JNJ, earnings

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.